Showing results (41-50 of 50) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
Cellular Immunology|June 1, 1989
Human peripheral blood T helper cell-induced B cell activation results in B cell surface expression of the CD23 (BLAST-2) antigenM K Crow, B Kushner, J A Jover, et al.
Arthritis and Rheumatism|November 1, 1996
Impaired recovery and cytolytic function of CD56+ T and non-T cells in systemic lupus erythematosus following in vitro polyclonal T cell stimulation. Studies in unselected patients and monozygotic disease-discordant twinsW Stohl, J E Elliott, A S Hamilton, et al.
Annals of the Rheumatic Diseases|December 5, 2008
Elevated synovial expression of triggering receptor expressed on myeloid cells 1 in patients with septic arthritis or rheumatoid arthritisC E Collins, D T La, H-T Yang, et al.
Annals of the Rheumatic Diseases|October 27, 2007
B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical responseG Cambridge, D A Isenberg, J C W Edwards, et al.
Annals of the Rheumatic Diseases|August 17, 2004
Inverse association between circulating APRIL levels and serological and clinical disease activity in patients with systemic lupus erythematosusW Stohl, S Metyas, S-M Tan, et al.
Lupus|May 30, 2018
A 6-month open-label extension study of the safety and efficacy of subcutaneous belimumab in patients with systemic lupus erythematosusA Doria, D Bass, A Schwarting, et al.
International Immunology|October 3, 2001
In vivo staphylococcal superantigen-driven polyclonal Ig responses in mice: dependence upon CD4(+) cells and human MHC class IIW Stohl, D Xu, S Zang, et al.
Annals of the Rheumatic Diseases|October 13, 2010
Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trialP P Tak, W F Rigby, A Rubbert-Roth, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 20, 2018
Efficacy and Safety of Subcutaneous Belimumab in Anti-Double-Stranded DNA-Positive, Hypocomplementemic Patients With Systemic Lupus ErythematosusA Doria, W Stohl, A Schwarting, et al.
Annals of the Rheumatic Diseases|August 22, 2015
Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled studyJ T Merrill, R F van Vollenhoven, J P Buyon, et al.
Pageof 5